The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
The Non-Malignant Channel is supported with funding from Agios (Gold).
The Sickle Cell Disease Channel is supported with funding from Agios (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH Erythro 2025 | Targeting heme-regulated inhibitor kinase in MDS-RS and sickle cell disease
Vera Adema, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the potential of targeting heme-regulated inhibitor (HRI) kinase to improve aberrant erythropoiesis in patients with myelodysplastic syndromes with ringed sideroblasts (MDS-RS) or sickle cell disease (SCD). Dr Adema notes that targeting HRI may also benefit patients with SCD by increasing fetal hemoglobin expression, which could alleviate anemia. This interview took place at the 4th ESH Translational Research Conference on Pathophysiology and Clinical Advances in Sickle Cell Disease and Thalassemia in Dublin, Ireland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
